NSCLC AND HEAD & NECK - found a doctors discussion
They rejected one and have agreed to fund the other; I’m working on writing the protocol for the funded one. This one is based on another signal seen in the big phase III trial referenced above–the elderly. With abraxane on a weekly schedule, there was much higher survival in older patients than with taxol on the every three week schedule–19.9 months vs. 10.4 months. The trial will be a 2nd line trial of abraxane on a weekly schedule for patients aged at least 70 years.
I will also disclose that I am not an unbiased source on anything abraxane related. I also have a head/neck cancer trial with Celgene using abraxane. All head/neck cancer is SqCC and the trial is for neo-adjuvant chemo given before chemorads for very advanced patients that we currently have a low rate of cure with standard therapy. Here, RR matters a lot and all patients are squamous. So far, this trial is going very well.
News 
Market Data 
Discover 
